Last reviewed · How we verify
LHRHa
LHRHa (Luteinizing Hormone-Releasing Hormone agonist) suppresses gonadal hormone production by desensitizing the pituitary gland to endogenous LHRH signaling.
LHRHa (Luteinizing Hormone-Releasing Hormone agonist) suppresses gonadal hormone production by desensitizing the pituitary gland to endogenous LHRH signaling. Used for Prostate cancer (hormone-sensitive), Breast cancer (hormone-sensitive), Endometriosis.
At a glance
| Generic name | LHRHa |
|---|---|
| Also known as | Lupron®, leuprolide, Zoladex®, goserelin |
| Sponsor | Imperial College London |
| Drug class | LHRH agonist |
| Target | LHRH receptor (GnRH receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
LHRHa drugs bind to LHRH receptors on pituitary gonadotroph cells, initially causing a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by receptor downregulation and sustained suppression of these hormones. This leads to reduced testosterone in males and estrogen in females, making these agents useful in hormone-dependent cancers and certain reproductive conditions.
Approved indications
- Prostate cancer (hormone-sensitive)
- Breast cancer (hormone-sensitive)
- Endometriosis
- Uterine fibroids
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Fatigue
- Gynecomastia
Key clinical trials
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PHASE3)
- Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma (PHASE2)
- Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (PHASE3)
- Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (PHASE3)
- Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa ) (NA)
- Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (PHASE3)
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |